2013-10-20 21:13:09 - Recently published research from CRI, "Research Report on China Measles, Mumps and Rubella (MMR) Vaccine Market, 2013-2017", is now available at Fast Market Research
Measles, mumps and rubella are major infectious diseases that threaten the health of children. Measles is a kind of acute respiratory infectious disease caused by measles virus with rashes covering the whole body. Mumps is a kind of respiratory infectious disease caused by mumps virus, which can violate organs including various gland tissues, nervous system, liver, kidney, heart, joint, etc. Rubella is a kind of acute respiratory infectious disease caused by rubella virus with light constitutional symptoms and lymphadenectasis behind the ears and on the necks, without koplik spots.
Full Report Details at
- www.fastmr.com/prod/698212_research_report_on_china_measles_mump ..
In China, the incidence rate of measles declines constantly in recent years. In 2012, the number of measles patients was 6,183, decreasing by 37.82% YOY, with
eight patients died of measles. In 2012, the incidence rate of measles was 4.6/100,000,000, which still lagged far behind the target set by WHO (incidence rate: below 1/100,000,000). In 2012, China's lot released volume of measles vaccines reached 8.651 million person-servings, decreasing by 43.5% YOY.
From 2010 to 2012, China's incidence rate of mumps increased year after year. In 2012, the number of mumps patients was 479,518, increasing by 5.53% YOY; the incidence rate was 354.1/100,000,000 without any death. In 2012, China's lot released volume of mumps vaccines was about 6.883 million person-servings, decreasing by 47% YOY.
In 2012, the number of rubella patients was 40,156 in China, decreasing by 38.74% YOY; the incidence rate was 29.7/100,000,000 and one patient died. In 2012, China's lot released volume of rubella vaccines was about 4.44 million person-servings, decreasing by 6.4% YOY.
Since domestic MMR vaccines were listed in China National Immunization Program in 2008, Chinese government has been providing eligible children with free MMR vaccines. If parents require imported MMR vaccines, it will at their own expenses.
According to long-term trend, MMR vaccines will gradually replace univalent vaccines or bivalent vaccines, becoming the mainstream in the market. During 2010 to 2012, China's lot released volume of MMR vaccines slightly declined, which mainly resulted from the fact that imported MMR vaccines were restricted. Along with the implementation of Pharmacopoeia of China (2010 Version), CFDA has not approved the MMR vaccine of GSK to be sold in China because it contains antibiotics. In 2011, a Chinese law office revealed that the MMR vaccines manufactured by Merck violated the approval process of imported vaccines in China because it lacked alerts in the specification and existed safety risks. During 2011 to 2012, China's legal import volume of MMR vaccines decreased sharply. As a result, China's total lot released volume of MMR vaccines also decreased to some extent.
In recent years, because China's newborn population is 16 million or even more every year, the prospect of MMR vaccines is promising. Although the import of MMR vaccines is restricted in China, many parents still choose imported MMR vaccines for their children out of the safety concern on domestic vaccines. These imported MMR vaccines are sold in some private clinics, which may come from smuggling.
Through this report, readers can acquire the following information:
* Government Policies and Events in China MMR Vaccine Market
* Supply Status of MMR Vaccines in China
* Market Demand of MMR Vaccines in China
* Major Enterprises Providing MMR Vaccines in China Market
* Factors Influencing the Development of China MMR Vaccine Market
* Prospect of China MMR Vaccine Market, 2013-2017
The following enterprises and people are proposed to purchase this report:
* Vaccine Manufacturing Enterprises
* Vaccine Trade Enterprises
* Medical Institutions
* Investors and Research Institutes Concerned About Vaccine Industry
Companies Mentioned in this Report: Shanghai Institute of Biological Products Co., Ltd. (SIBP), Beijing Tiantan Biological Products Co., Ltd."
About Fast Market Research
Fast Market Research is an online aggregator and distributor of market research and business information. We represent the world's top research publishers and analysts and provide quick and easy access to the best competitive intelligence available.
For more information about these or related research reports, please visit our website at www.fastmr.com
or call us at 1.800.844.8156.